» Articles » PMID: 22005999

Impact of Inadequate Empirical Therapy on the Mortality of Patients with Bloodstream Infections: a Propensity Score-based Analysis

Abstract

The impact of the adequacy of empirical therapy on outcome for patients with bloodstream infections (BSI) is key for determining whether adequate empirical coverage should be prioritized over other, more conservative approaches. Recent systematic reviews outlined the need for new studies in the field, using improved methodologies. We assessed the impact of inadequate empirical treatment on the mortality of patients with BSI in the present-day context, incorporating recent methodological recommendations. A prospective multicenter cohort including all BSI episodes in adult patients was performed in 15 hospitals in Andalucía, Spain, over a 2-month period in 2006 to 2007. The main outcome variables were 14- and 30-day mortality. Adjusted analyses were performed by multivariate analysis and propensity score-based matching. Eight hundred one episodes were included. Inadequate empirical therapy was administered in 199 (24.8%) episodes; mortality at days 14 and 30 was 18.55% and 22.6%, respectively. After controlling for age, Charlson index, Pitt score, neutropenia, source, etiology, and presentation with severe sepsis or shock, inadequate empirical treatment was associated with increased mortality at days 14 and 30 (odds ratios [ORs], 2.12 and 1.56; 95% confidence intervals [95% CI], 1.34 to 3.34 and 1.01 to 2.40, respectively). The adjusted ORs after a propensity score-based matched analysis were 3.03 and 1.70 (95% CI, 1.60 to 5.74 and 0.98 to 2.98, respectively). In conclusion, inadequate empirical therapy is independently associated with increased mortality in patients with BSI. Programs to improve the quality of empirical therapy in patients with suspicion of BSI and optimization of definitive therapy should be implemented.

Citing Articles

Advancing rapid diagnostics for bloodstream infections: a perspective on scattered light integrated collection technology.

Ghogale S, Pathak K J Med Microbiol. 2025; 74(3).

PMID: 40072045 PMC: 11903646. DOI: 10.1099/jmm.0.001973.


Retrospective analysis of 300 microbial cell-free DNA sequencing results in routine blood stream infection diagnostics.

Neidhofer C, Klein N, Yuruktumen A, Hattenhauer T, Mispelbaum R, Bode C Front Cell Infect Microbiol. 2025; 15:1504262.

PMID: 39949721 PMC: 11821936. DOI: 10.3389/fcimb.2025.1504262.


Investigating the time to blood culture positivity: why does it take so long?.

Falconer K, Hammond R, Parcell B, Gillespie S J Med Microbiol. 2025; 74(1).

PMID: 39757997 PMC: 11701752. DOI: 10.1099/jmm.0.001942.


Performance evaluation of the Specific Reveal system for rapid antibiotic susceptibility testing from positive blood cultures containing Gram-negative pathogens.

Ostermann G, Korber-Irrgang B, Kruger A, Singh P, Vo K, Gielen J J Clin Microbiol. 2024; 62(12):e0069224.

PMID: 39545740 PMC: 11633213. DOI: 10.1128/jcm.00692-24.


Antibiotic stewardship bundle for uncomplicated gram-negative bacteremia at an academic health system: a quasi-experimental study.

DiPietro J, Dubrovskaya Y, Marsh K, Decano A, Papadopoulos J, Mazo D Antimicrob Steward Healthc Epidemiol. 2024; 4(1):e171.

PMID: 39411661 PMC: 11474889. DOI: 10.1017/ash.2024.395.


References
1.
Paul M, Fraser A, Leibovici L . Propensity-matched analysis of appropriate empirical antibiotic treatment. Clin Infect Dis. 2007; 44(9):1251-2. DOI: 10.1086/513585. View

2.
Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

3.
Rodriguez-Bano J, Pascual A, Galvez J, Muniain M, Rios M, Martinez-Martinez L . [Acinetobacter baumannii bacteremia: clinical and prognostic features]. Enferm Infecc Microbiol Clin. 2003; 21(5):242-7. DOI: 10.1016/s0213-005x(03)72930-9. View

4.
Lesens O, Methlin C, Hansmann Y, Remy V, Martinot M, Bergin C . Role of comorbidity in mortality related to Staphylococcus aureus bacteremia: a prospective study using the Charlson weighted index of comorbidity. Infect Control Hosp Epidemiol. 2004; 24(12):890-6. DOI: 10.1086/502156. View

5.
Lin M, Weinstein R, Hota B . Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrob Agents Chemother. 2008; 52(9):3188-94. PMC: 2533498. DOI: 10.1128/AAC.01553-07. View